Skip to content
Screener

Dianthus Therapeutics DNTH Q2 2025 earnings

Reported August 7, 2025 · Before market open

Revenue$193.0KMiss by $671.7K
EPS-$0.88Miss by $0.02
Revenue estimate$864.7K
EPS estimate-$0.86

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$443.9K
EPS estimate-$0.94

Financials

Q2 2025

Income statement

See full
Revenue$193.0K-89.6%
Operating income-$34.9M-57.3%
Net income-$31.6M-79.6%
EPS (diluted)-$0.88-72.5%

Balance sheet

See full
Cash & equivalents$13.2M-95.8%
Total debt$1.3M+227%
Total equity$303.1M-15.4%
Total assets$326.1M-11.6%

Cash flow

See full
Operating cash flow-$23.9M-64.5%
CapEx$46.0K+171%
Free cash flow-$23.9M-64.6%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$583.38M-34.1%
Enterprise value$571.48M-0.1%
P/S120.2×-94.9×

Profitability

See full
Operating margin-2,676.6%+4,064pp
Net margin-2,364.1%+6,007pp
FCF margin-2,067.6%+4,049pp

Returns & leverage

See full
Return on equity-34.7%—
Debt / equity0×0.0×
Current ratio13.1×-23.3×

Segments

By product

See full
License$193.0K-89.6%

FAQ

When did Dianthus Therapeutics report Q2 2025 earnings?
Dianthus Therapeutics (DNTH) reported Q2 2025 earnings on August 7, 2025 before market open.
What were Dianthus Therapeutics's Q2 2025 revenue and EPS?
Dianthus Therapeutics reported revenue of $193.0K and eps of $-0.88 for Q2 2025.
Did Dianthus Therapeutics beat estimates in Q2 2025?
Revenue missed the consensus estimate of $864.7K by $671.7K. EPS missed the consensus estimate of $-0.86 by $0.02.
How did Dianthus Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 89.6% from $1.9M a year earlier and eps declined 72.5% from $-0.51.
Where can I find Dianthus Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-105002) and the 10-Q periodic report (0000950170-25-105030) directly on SEC EDGAR. The filing index links above go to sec.gov.